The randomized, double-blind, sham-controlled clinical trial [108] investigated the effects of bilateral tDCS on craving, tumor necrosis factor-alpha (TNF-a) and interleukin-6 (IL-6) expression levels, and impulsivity in adult males with opioid use disorder (OUD). This evidence concerns the gene IL6 and opioid use disorder.